These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1904356)

  • 1. Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
    Miettinen TA
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S19-21. PubMed ID: 1904356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape phenomenon occurs by lowering cholesterol with a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia.
    Yamamoto A; Yokoyama S; Yamamura T
    Atherosclerosis; 1988 Jun; 71(2-3):257-60. PubMed ID: 3135813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
    Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
    Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors.
    Sirtori CR
    Pharmacol Res; 1990; 22(5):555-63. PubMed ID: 2126139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits.
    Ishida F; Watanabe K; Sato A; Taguchi K; Kakubari K; Kitani K; Kamei T
    Biochim Biophys Acta; 1990 Feb; 1042(3):365-73. PubMed ID: 2106347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lovastatin on cholesterol absorption in cholesterol-fed rabbits.
    Nielsen LB; Stender S; Kjeldsen K
    Pharmacol Toxicol; 1993 Mar; 72(3):148-51. PubMed ID: 8516264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Islam F; Watanabe Y; Hayaishi O
    Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
    Hoogerbrugge-vd Linden N; de Rooy FW; Jansen H; van Blankenstein M
    Gut; 1990 Mar; 31(3):348-50. PubMed ID: 2108908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors].
    Ribeiro L; Kohn IJ
    Arq Bras Cardiol; 1990 Mar; 54(3):177-8. PubMed ID: 2288502
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H; Weidmann P; Riesen WF; Beretta-Piccoli C; Fragiacomo C; Wunderlin R; Noseda G
    Eur J Clin Pharmacol; 1990; 39(2):101-5. PubMed ID: 2123791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin: a new drug for the treatment of hypercholesterolemia.
    Jungnickel PW; Cantral KA; Maloley PA
    Clin Pharm; 1992 Aug; 11(8):677-89. PubMed ID: 1511541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational therapy of familial hypercholesterolemia.
    Reynolds GA
    Circulation; 1989 May; 79(5):1146-8. PubMed ID: 2496938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.